Evodiamine derivatives improve cognitive abilities in APP

evodiamine derivatives mouse model neuroprotective spatial memory

Journal

Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 30 03 2020
revised: 27 05 2020
accepted: 29 05 2020
entrez: 3 7 2020
pubmed: 3 7 2020
medline: 3 7 2020
Statut: epublish

Résumé

Alzheimer's disease (AD) is a complex neurodegenerative disease. Due to the complexity of its molecular pathogenesis and the interaction of the numerous factors involved, the etiology and pathogenesis of AD have not been fully elucidated. Therefore, effective treatment for AD remains to be developed. Evodiamine, a quinolone alkaloid, has been found to improve learning and memory ability to in the APP Evodiamine and its derivatives were effectively synthesized by EDCI-mediated condensation at room temperature. These target compounds contained 1 thio- and 21 oxo-evodiamine derivatives with different substituted groups. The cytotoxicity of evodiamine and its derivatives and the neuroprotective effects of the evodiamine derivatives against H In this study, a series of oxo- and thio-evodiamine derivatives was synthesized. Several derivatives showed lower cytotoxicity and stronger neuroprotective effects than evodiamine and elicited enhanced cognitive improvement, especially in the test of spatial memory in APP Our study provides insights for developing novel evodiamine derivatives for chemical intervention and treatment of AD.

Sections du résumé

BACKGROUND BACKGROUND
Alzheimer's disease (AD) is a complex neurodegenerative disease. Due to the complexity of its molecular pathogenesis and the interaction of the numerous factors involved, the etiology and pathogenesis of AD have not been fully elucidated. Therefore, effective treatment for AD remains to be developed. Evodiamine, a quinolone alkaloid, has been found to improve learning and memory ability to in the APP
METHODS METHODS
Evodiamine and its derivatives were effectively synthesized by EDCI-mediated condensation at room temperature. These target compounds contained 1 thio- and 21 oxo-evodiamine derivatives with different substituted groups. The cytotoxicity of evodiamine and its derivatives and the neuroprotective effects of the evodiamine derivatives against H
RESULTS RESULTS
In this study, a series of oxo- and thio-evodiamine derivatives was synthesized. Several derivatives showed lower cytotoxicity and stronger neuroprotective effects than evodiamine and elicited enhanced cognitive improvement, especially in the test of spatial memory in APP
CONCLUSION CONCLUSIONS
Our study provides insights for developing novel evodiamine derivatives for chemical intervention and treatment of AD.

Identifiants

pubmed: 32613178
doi: 10.1002/ame2.12126
pii: AME212126
pmc: PMC7323704
doi:

Types de publication

Journal Article

Langues

eng

Pagination

193-199

Informations de copyright

© 2020 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.

Déclaration de conflit d'intérêts

None.

Références

Biol Pharm Bull. 2018 May 1;41(5):722-732
pubmed: 29445054
Chem Commun (Camb). 2016 Oct 25;52(87):12869-12872
pubmed: 27735960
Molecules. 2009 May 18;14(5):1852-9
pubmed: 19471205
Pharmacol Res. 2019 Mar;141:541-550
pubmed: 30616017
Biol Psychiatry. 2018 Feb 15;83(4):300-310
pubmed: 28666525
EBioMedicine. 2015 Nov 03;2(12):1888-904
pubmed: 26844268
Acta Pharmacol Sin. 2011 Mar;32(3):295-302
pubmed: 21278785
Chin J Nat Med. 2017 Sep;15(9):641-652
pubmed: 28991525
Planta Med. 2005 May;71(5):416-9
pubmed: 15931578
J Vis Exp. 2011 Jul 20;(53):
pubmed: 21808223
N Biotechnol. 2017 Oct 25;39(Pt B):190-198
pubmed: 28579476
Cell Mol Neurobiol. 2019 Mar;39(2):181-209
pubmed: 30671696
Cell Mol Neurobiol. 2014 Oct;34(7):973-85
pubmed: 24848007
Aging (Albany NY). 2019 Dec 9;11(23):11186-11201
pubmed: 31816602
Brain Res Bull. 2009 Oct 28;80(4-5):268-73
pubmed: 19683563
Sci Transl Med. 2011 Apr 6;3(77):77sr1
pubmed: 21471435
Nat Rev Immunol. 2018 Dec;18(12):759-772
pubmed: 30140051
Sci Rep. 2016 Mar 08;6:22635
pubmed: 26951766
Int Rev Neurobiol. 2017;135:29-56
pubmed: 28807163
BMC Complement Altern Med. 2014 Aug 05;14:286
pubmed: 25091565
Fitoterapia. 2015 Oct;106:22-35
pubmed: 26255828
N Engl J Med. 2010 Jan 28;362(4):329-44
pubmed: 20107219
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20284-9
pubmed: 24277810
Mol Med Rep. 2014 Mar;9(3):947-54
pubmed: 24366367
Learn Behav. 2019 Mar;47(1):29-37
pubmed: 29520732
Molecules. 2008 Feb 06;13(2):272-300
pubmed: 18305418
Am J Geriatr Psychiatry. 2004 May-Jun;12(3):250-7
pubmed: 15126225

Auteurs

Shuo Pang (S)

Key Laboratory of Human Disease Comparative Medicine National Health Commission of China (NHC) Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Beijing Engineering Research Center for Experimental Animal Models of Human Diseases Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.

Caixian Sun (C)

Key Laboratory of Human Disease Comparative Medicine National Health Commission of China (NHC) Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Beijing Engineering Research Center for Experimental Animal Models of Human Diseases Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.

Shan Gao (S)

Key Laboratory of Human Disease Comparative Medicine National Health Commission of China (NHC) Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Beijing Engineering Research Center for Experimental Animal Models of Human Diseases Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.

Yajun Yang (Y)

Beijing Key Laboratory of Active Substance Discovery and Drug ability Evaluation Institute of Material Medical Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

Xiandao Pan (X)

Beijing Key Laboratory of Active Substance Discovery and Drug ability Evaluation Institute of Material Medical Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

Lianfeng Zhang (L)

Key Laboratory of Human Disease Comparative Medicine National Health Commission of China (NHC) Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Beijing Engineering Research Center for Experimental Animal Models of Human Diseases Institute of Laboratory Animal Science Peking Union Medical College Chinese Academy of Medical Sciences Beijing China.
Neuroscience Center Chinese Academy of Medical Sciences Beijing China.

Classifications MeSH